© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
November 16, 2021
October 27, 2021
September 16, 2021
August 17, 2021
The FDA has approved Qelbree (viloxazine extended-release capsules; Supernus Pharmaceuticals, Inc) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in pediatric patients aged 6 to 17 years.
July 27, 2021
Evkeeza has been approved as an adjunct to other low-density lipoprotein cholesterol-lowering therapies to treat patients 12 years and older with homozygous familial hypercholesterolemia.
May 21, 2021
The FDA has approved Verquvo (vericiguat; Merck) tablets for adults with chronic heart failure.